Pharmalink AB receives patent for Nefecon® principle. Japanese grant supports Asian partnering program.

Pharmalink AB completes Phase II clinical study with renal disease drug Nefecon

Pharmalink AB strengthens board of directors and signals a strategic step towards late product development